Search

Janus kinase inhibitors are emerging treatment alternatives in various immune-mediated diseases including alopecia universalis. Herein, we report a patient with psoriasis and alopecia universalis in whom treatment with tofacitinib led to remission of psoriasis without improvement in alopecia universalis. Despite the promising potential in alopecia areata treatment, research evaluating the efficacy of different Janus kinase inhibitors and possible prognostic factors related with a more favorable response are warranted.

Background: There is a lack of real-life safety data on treatment options for chronic urticaria in the presence of comedication and comorbidities. Methods: We present a single-center UCARE pilot study of 212 outpatients with chronic urticaria. Patients were divided into three groups according to different CU therapies according to international guidelines. Results: Of 212 patients, 108 (mean age 48.9years, 71.3% female) had 59 comorbidities, including cardiovascular, autoimmune and malignant diseases. Patients were followed for a mean of 24.6months (SD ± 21.3). Urticaria therapies were divided into three groups: A: 105 (97.2%) with omalizumab and 2nd generation antihistamines), B: 16 patients (14.8%): dual therapy with antihistamines and cyclosporine in 10 (9.3%), montelukast in five (4. 6%), dapsone in four (3.7%), hydroxychloroquine in one patient (0.9%), C: 12 (11.1%) patients received a third drug for 4.9months (SD ± 3.2) and one quadruple therapy (2.1months). 10 out of 12 (83.3%) patients received montelukast, two (16.7%) cyclosporine, two (16.7%) dapsone and one (8.3%) hydroxychloroquine as a third drug for chronic urticaria. Conclusions: Combining treatment modalities for chronic urticaria and comorbidities are available and feasible with a good safety profile. [ABSTRACT FROM AUTHOR]

Keratitis-ichthyosis-deafness (KID) syndrome is a rare genodermatosis causing ichthyosis-like skin lesions, keratitis, and deafness. Herein, we report a patient with this rare syndrome in association with pityriasis lichenoides chronica, which was succesfully treated with narrow-band ultraviolet B phototherapy despite our concerns regarding the increased risk of squamous cell carcinoma, hyperpyrexia, and keratitis.

Byline: Tulin. Ergun, Vildan. Yazici, Dilek. Yavuz, Dilek. Seckin-Gencosmanoglu, Gulsen. Ozen, Andac. Salman, Haner. Direskeneli, Nevsun. Inanc Context: Advanced glycation end products (AGEs) promote oxidative stress and inflammation by altering [...]

Byline: Burak. Tekin, Andac. Salman, Tulin. Ergun Sir, Hidradenitis suppurativa is a chronic disorder manifesting with relapsing, deep-seated nodules and abscesses in the inverse body areas which have a tendency [...]

Byline: Andac. Salman, Burak. Tekin, Deniz. Yucelten Background: Autoimmune bullous disorders (AIBDs) are a heterogeneous group of diseases which are rarely seen in children. Studies concerning the immunobullous diseases in [...]

Byline: Tulin. Ergun, Dilek. Seckin-Gencosmanoglu, Andac. Salman, Zuleyha. Ozgen, Esra. Ocak, Erol. Avsar, Nese. Imeryuz Patients with psoriasis are at an increased risk of developing liver disease due to various [...]

Byline: Tulin. Ergun, Dilek. Seckin, Andac. Salman, Esra. Ocak, Ayse. Yucelten, Haner. Direskeneli, Cuyan. Demirkesen, Gazanfer. Ekinci, Mahmut. Bayik Eosinophilic fasciitis is an uncommon connective tissue disease that may mimic [...]

Byline: Burak. Tekin, Andac. Salman, Serhan. Tuglular, Derya. Guler, Gulsen. Ozen, Haner. Direskeneli, Fatma. Ayranci, Leyla. Cinel, Tulin. Ergun Sir, A 41-year-old man with ankylosing spondylitis, familial Mediterranean fever (homozygous [...]

Byline: Andac. Salman, Ayse. Yucelten, Dilek. Seckin, Tulin. Ergun, Zeynep. Demircay Sir, An 86-year-old Turkish woman from the southeastern Anatolia region presented with an erythematous and crusted plaque on her [...]

Atopic dermatitis (AD) is a common, chronic inflammatory condition with a substantial negative impact on the quality of life. Dupilumab, the first biologic approved for the treatment of moderate‐to‐severe AD, binds IL‐4Rα and inhibits signaling of both IL‐4 and IL‐13. This study aimed to determine the real‐life effectiveness and safety of dupilumab treatment in patients with moderate‐to‐severe AD. The results of the study indicates high effectiveness and safety of dupilumab in real‐life conditions. The treatment was continued during the COVID‐19 pandemic in most of the patients without any adverse outcome. The rate of conjunctivitis was higher compared to clinical trials, nevertheless treatment was not discontinued in any patients due to adverse effects. [ABSTRACT FROM AUTHOR]

Background: The real-life data on the effectiveness and safety of omalizumab in chronic spontaneous urticaria (CSU) with validated methods are scarce. There is also a lack of information on the use of combination treatments. Methods: A retrospective cohort study was done to evaluate the effectiveness and safety of omalizumab in real-life conditions. The patients with CSU treated with omalizumab between 2015 and 2018 were included. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT). Results: A total of 106 patients were included. A complete response (CR) (UAS7:0) and a well-controlled activity (WCA) (UAS7:1 to <6) were observed in 50 (47.2%) and 35 (33%) patients, respectively. The number of patients with an UCT score ≥12 was also significantly increased. Higher rates of CR/WCA were observed with omalizumab monotherapy compared to combination with antihistamines. The combination of dapsone, colchicine, and omalizumab provided additional benefit in a small group. Conclusion: Treatment with omalizumab provided a rapid and sustainable improvement in real-life settings. The use of omalizumab as monotherapy or combined with antihistamines does not show differences in the treatment response. The combination of omalizumab with immunomodulatory agents might be of benefit in selected cases. [ABSTRACT FROM AUTHOR]